Genfit SA, a biopharmaceutical company, develops therapeutic and diagnostic solutions to address high unmet patient needs in metabolic and inflammatory diseases with a focus on the liver and gastroenterology worldwide. It offers diagnostic solutions in various therapeutic areas, such as metabolic diseases, liver diseases, non-alcoholic steato-hepatitis (NASH), cholestatic liver diseases, inflammation and autoimmune diseases, and inflammatory bowel diseases. The companys lead pipeline product comprises GFT505, which is in Phase II clinical trials for the treatment of NASH. It is also developing TGFTX1 program that targets the RORgamma-t receptor, which directs IL-17 mediated immunity to treat inflammatory and auto-immune diseases; and TGFTX3 program for developing proprietary compounds, which activate the nuclear receptor Rev-Erba for metabolic and inflammatory diseases, including NASH and type 2 diabetes. The company also develops TGFTX4 program that inhibits the proliferation and the pro-fibrotic activation of primary human hepatic stellate cells; TGFTX5 program for chronic inflammatory bowel diseases; and SAN/GFT-2 program to develop molecules, which correct the mitochondrial dysfunction associated with certain pathologies comprising type 2 diabetes and kidney diseases. Genfit SA was founded in 1999 and is headquartered in Loos, France.